ASX:TLXBiotechs
How Investors May Respond To Telix Pharmaceuticals (ASX:TLX) Upgraded FY26 Guidance And Pipeline Milestones
In July 2026, Telix Pharmaceuticals reported positive Phase 1 ProstACT SELECT data for its PSMA-targeting rADC TLX591-Tx, dosed the first patient in the Phase 3 LUTEON trial for TLX250-Tx in clear cell renal cell carcinoma, entered a collaboration with Regeneron Pharmaceuticals on radiopharmaceutical therapies, and raised its Fiscal Year 2026 revenue guidance to above US$1 billion alongside higher quarterly revenue of US$247 million.
Together, these updates underscore Telix's attempt to...